August 2013

Plausibility and the role of post-published evidence in UK litigation
The Court of Appeal has dismissed Mylan’s appeal against the High Court’s decision upholding the European patent (UK) protecting Teva’s largest branded drug, the multiple sclerosis treatment Copaxone®.
Read More
29
Aug
2013
hES cell patents in Europe – what’s the point?
The ECJ’s previous decision has been interpreted to mean that use of hES cells from established cell lines obtained by "destructive methods" is not patentable. In spite of this, you may be able to get claims granted by the European Patent Office (EPO) which on their face encompass hES cells. But is there any point in getting claims like this granted, or is there freedom to operate?
Read More
22
Aug
2013
Broccoli and tomatoes
EPO Enlarged Board of Appeal defines the extent to which plant crossing and selection processes are excluded from patentability as essentially biological processes under Article 53(b) EPC.
Read More
20
Aug
2013

Type

Service

Sector

Archive